Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous JKN2401 in moderate-to-severe COPD (Phase II, randomized, double-blind, placebo-controlled)
CTR20261238Phase 2Active
- Sponsor
- Quxin Biopharmaceutical
- Start
- Apr 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of JKN2401 in chronic obstructive pulmonary disease (COPD), sponsored by Quxin Biopharmaceutical. Started Apr 2026; status: active.
02
Drugs
JKN2401
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on CTR20261238.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261238.